US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Savara Inc

5.36

-0.0300-0.56%

Volume:526.60K

Turnover:2.82M

Market Cap:1.10B

PE:-9.27

High:5.41

Open:5.32

Low:5.29

Close:5.39

52wk High:7.01

52wk Low:3.21

Shares:204.66M

Float Shares:198.20M

Volume Ratio:0.40

T/O Rate:0.27%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.5782

EPS(LYR):-0.5344

ROE:-105.48%

ROA:-50.15%

PB:7.64

PE(LYR):-10.03

Loading ...

Overview Company News Filings

A Look At Savara (SVRA) Valuation After Strong 1 Year Shareholder Return

Simply Wall St.

Savara publishes corporate presentation highlighting MOLBREEVI program in autoimmune PAP

FDA extends Savara molgramostim BLA review, pushing PDUFA date to Nov. 22, 2026

Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (Bla) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune Pap)

THOMSON REUTERS

Savara Inc: Prescription Drug User Fee Act (Pdufa) Target Action Date Extended by Three Months to November 22, 2026

THOMSON REUTERS

Savara presents new Phase 3 IMPALA-2 molgramostim data at ATS 2026

Savara announces annual shareholder meeting via webcast

BUZZ-Savara rises as UK accepts application for rare lung disease drug

Savara Announces The U.K. Medicines And Healthcare Products Regulatory Agency (Mhra) Has Accepted The Molbreevi* Marketing Authorisation Application (Maa) For Autoimmune Pulmonary Alveolar Prote

Savara publishes corporate presentation highlighting MOLBREEVI autoimmune PAP Phase 3 data

Savara announces MHRA accepted submission of Molbreevi MAA

Savara says UK MHRA accepts Molbreevi filing for autoimmune PAP under accelerated review

Savara Inc - Mhra Decision on Molbreevi Maa Expected in Q4 2026

THOMSON REUTERS

Savara Announces the U.k. Medicines and Healthcare Products Regulatory Agency (Mhra) Has Accepted the Molbreevi* Marketing Authorisation Application (Maa) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune Pap)

THOMSON REUTERS

Savara Inc - FDA Pdufa Date for Molbreevi Bla Set for August 22, 2026

THOMSON REUTERS

A Look At Savara (SVRA) Valuation As MOLBREEVI Nears Key Regulatory Decisions In Rare Lung Disease

Simply Wall St.

Savara publishes corporate presentation spotlighting MOLBREEVI Phase 3 progress in autoimmune PAP

Savara announces EMA validation of MAA for MOLBREEVI

Savara says EMA validates MOLBREEVI marketing application for autoimmune PAP

Savara Inc - Molbreevi Bla Under FDA Priority Review With August 22, 2026 Action Date

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/SVRA/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SVRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SVRA\",,,,,undefined,":{"symbol":"SVRA","market":"US","secType":"STK","nameCN":"Savara Inc","latestPrice":5.36,"timestamp":1788288387888,"preClose":5.39,"halted":0,"volume":526601,"delay":0,"changeRate":-0.0055658627087197335,"floatShares":198198210,"shares":204657499,"eps":-0.578152,"marketStatus":"Trading","change":-0.03,"latestTime":"09-01 14:46:28 EDT","open":5.32,"high":5.405,"low":5.29,"amount":2817762.9608500004,"amplitude":0.021336,"askPrice":5.36,"askSize":1424,"bidPrice":5.35,"bidSize":900,"shortable":3,"etf":0,"ttmEps":-0.578152,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788292800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":5.39,"preHourTrading":{"tag":"盘前","latestPrice":5.33,"preClose":5.39,"latestTime":"09:29 EDT","volume":10022,"amount":53960.65284,"timestamp":1788269347023,"change":-0.06,"changeRate":-0.011132,"amplitude":0.022263},"postHourTrading":{"tag":"盘后","latestPrice":5.51,"preClose":5.39,"latestTime":"19:30 EDT","volume":38639,"amount":208434.94742,"timestamp":1788219002171,"change":0.12,"changeRate":0.022263,"amplitude":0.022263},"volumeRatio":0.403435,"impliedVol":2.213,"impliedVolPercentile":0.7698},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SVRA\",,,,,undefined,":{"symbol":"SVRA","floatShares":198198210,"roa":"-50.15%","roe":"-105.48%","lyrEps":-0.534368,"volumeRatio":0.403435,"shares":204657499,"dividePrice":0,"high":5.405,"amplitude":0.021336,"preClose":5.39,"low":5.29,"week52Low":3.21,"pbRate":"7.64","week52High":7.005,"institutionHeld":0.8524,"latestPrice":5.36,"committee":-0.225473,"eps":-0.578152,"divideRate":0,"volume":526601,"delay":0,"ttmEps":-0.578152,"open":5.32,"prevYearClose":6.03,"prevWeekClose":5.26,"prevMonthClose":5.39,"prevQuarterClose":6.16,"fiveDayClose":5.6,"twentyDayClose":5.41,"sixtyDayClose":5.09},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SVRA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"SVRA","fiscalQuarterEnding":"2026/06","expectedEps":-0.14,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"post","actualEps":-0.16},{"market":"US","date":"2026-05-12","symbol":"SVRA","fiscalQuarterEnding":"2026/03","expectedEps":-0.14,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"post","actualEps":-0.15},{"market":"US","date":"2026-03-13","symbol":"SVRA","fiscalQuarterEnding":"2025/12","expectedEps":-0.12,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1773374400000,"reportTimeType":"pre","actualEps":-0.13},{"market":"US","date":"2025-11-12","symbol":"SVRA","fiscalQuarterEnding":"2025/09","expectedEps":-0.13,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"post","actualEps":-0.14},{"market":"US","date":"2025-08-13","symbol":"SVRA","fiscalQuarterEnding":"2025/06","expectedEps":-0.12,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"pre","actualEps":-0.14}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SVRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SVRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.375,"buy":0.625,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.625,"analysts":8,"updateTime":1760673600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SVRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SVRA","date":"2026-08-31","current":-9.322808,"percent":0.349878,"low":-15.250395,"twenty":-11.474987,"median":-7.222117,"eighty":-4.147533,"high":-2.605866,"avg":-7.683512,"sd":3.393347,"marketCap":1336765985},"quantilePoints":[{"date":"2021-09-03","current":-3.839347,"twenty":-11.217586,"median":-4.410492,"eighty":-1.410882,"marketCap":176464062},{"date":"2021-09-10","current":-3.591647,"twenty":-10.802353,"median":-4.401307,"eighty":-1.415446,"marketCap":165079283},{"date":"2021-09-17","current":-3.443027,"twenty":-10.699669,"median":-4.3851,"eighty":-1.417737,"marketCap":158248416},{"date":"2021-09-24","current":-3.220097,"twenty":-10.679132,"median":-4.375718,"eighty":-1.417751,"marketCap":148002116},{"date":"2021-10-01","current":-3.319177,"twenty":-10.442959,"median":-4.367971,"eighty":-1.417751,"marketCap":152556027},{"date":"2021-10-08","current":-3.294407,"twenty":-10.432691,"median":-4.350129,"eighty":-1.430744,"marketCap":151417550},{"date":"2021-10-15","current":-3.195327,"twenty":-10.391617,"median":-4.34948,"eighty":-1.433771,"marketCap":146863638},{"date":"2021-10-22","current":-2.997168,"twenty":-10.330007,"median":-4.326588,"eighty":-1.433771,"marketCap":137755816},{"date":"2021-10-29","current":-2.873318,"twenty":-10.330007,"median":-4.278431,"eighty":-1.441065,"marketCap":132063427},{"date":"2021-11-05","current":-2.972398,"twenty":-10.206786,"median":-4.233525,"eighty":-1.441781,"marketCap":136617338},{"date":"2021-11-12","current":-2.831373,"twenty":-10.199059,"median":-4.210516,"eighty":-1.441781,"marketCap":128671754},{"date":"2021-11-19","current":-2.706091,"twenty":-10.024453,"median":-4.202795,"eighty":-1.441781,"marketCap":122978313},{"date":"2021-11-26","current":-2.881486,"twenty":-9.917635,"median":-4.190578,"eighty":-1.443357,"marketCap":130949130},{"date":"2021-12-03","current":-2.655978,"twenty":-9.874496,"median":-4.159412,"eighty":-1.454242,"marketCap":120700937},{"date":"2021-12-10","current":-2.605866,"twenty":-9.788221,"median":-4.129491,"eighty":-1.457614,"marketCap":118423561},{"date":"2021-12-17","current":-2.956655,"twenty":-9.743029,"median":-4.105056,"eighty":-1.462169,"marketCap":134365194},{"date":"2021-12-23","current":-3.232276,"twenty":-9.69989,"median":-4.096593,"eighty":-1.463261,"marketCap":146890763},{"date":"2021-12-31","current":-3.106994,"twenty":-9.673793,"median":-4.05298,"eighty":-1.463326,"marketCap":141197323},{"date":"2022-01-07","current":-3.282388,"twenty":-9.655788,"median":-4.006708,"eighty":-1.46638,"marketCap":149168139},{"date":"2022-01-14","current":-3.257332,"twenty":-9.570476,"median":-3.985431,"eighty":-1.469278,"marketCap":148029451},{"date":"2022-01-21","current":-2.881486,"twenty":-9.517068,"median":-3.938427,"eighty":-1.471159,"marketCap":130949130},{"date":"2022-01-28","current":-2.85643,"twenty":-9.509957,"median":-3.909431,"eighty":-1.473381,"marketCap":129810442},{"date":"2022-02-04","current":-3.081937,"twenty":-9.504428,"median":-3.896613,"eighty":-1.474842,"marketCap":140058635},{"date":"2022-02-11","current":-3.006768,"twenty":-9.486889,"median":-3.881309,"eighty":-1.476376,"marketCap":136642570},{"date":"2022-02-18","current":-2.78126,"twenty":-9.460663,"median":-3.84849,"eighty":-1.477623,"marketCap":126394377},{"date":"2022-02-25","current":-2.756204,"twenty":-9.445342,"median":-3.839347,"eighty":-1.479961,"marketCap":125255689},{"date":"2022-03-04","current":-2.756204,"twenty":-9.43811,"median":-3.808811,"eighty":-1.482282,"marketCap":125255689},{"date":"2022-03-11","current":-2.706091,"twenty":-9.431308,"median":-3.768435,"eighty":-1.484092,"marketCap":122978313},{"date":"2022-03-18","current":-3.257332,"twenty":-9.410249,"median":-3.731396,"eighty":-1.486429,"marketCap":148029451},{"date":"2022-03-25","current":-3.081937,"twenty":-9.366646,"median":-3.708504,"eighty":-1.4958,"marketCap":140058635},{"date":"2022-04-01","current":-3.499619,"twenty":-9.311844,"median":-3.597148,"eighty":-1.497733,"marketCap":150532615},{"date":"2022-04-08","current":-3.499619,"twenty":-9.262945,"median":-3.56335,"eighty":-1.505113,"marketCap":150532615},{"date":"2022-04-14","current":-3.340545,"twenty":-9.257117,"median":-3.542107,"eighty":-1.505113,"marketCap":143690223},{"date":"2022-04-22","current":-3.261009,"twenty":-9.233589,"median":-3.521352,"eighty":-1.505113,"marketCap":140269027},{"date":"2022-04-29","current":-3.128447,"twenty":-9.200262,"median":-3.499619,"eighty":-1.510539,"marketCap":134567034},{"date":"2022-05-06","current":-3.048911,"twenty":-9.104739,"median":-3.444811,"eighty":-1.510539,"marketCap":131145839},{"date":"2022-05-13","current":-3.468662,"twenty":-9.032946,"median":-3.420082,"eighty":-1.510539,"marketCap":142551588},{"date":"2022-05-20","current":-3.801653,"twenty":-8.916829,"median":-3.420082,"eighty":-1.510539,"marketCap":156236541},{"date":"2022-05-27","current":-3.662907,"twenty":-8.862364,"median":-3.420082,"eighty":-1.510539,"marketCap":150534477},{"date":"2022-06-03","current":-3.746155,"twenty":-8.73459,"median":-3.420082,"eighty":-1.510539,"marketCap":153955715},{"date":"2022-06-10","current":-3.91265,"twenty":-8.186259,"median":-3.420082,"eighty":-1.510539,"marketCap":160798192},{"date":"2022-06-17","current":-3.607408,"twenty":-7.972847,"median":-3.420082,"eighty":-1.510539,"marketCap":148253652},{"date":"2022-06-24","current":-4.356639,"twenty":-7.810479,"median":-3.420082,"eighty":-1.509183,"marketCap":179044795},{"date":"2022-07-01","current":-4.273391,"twenty":-7.710825,"median":-3.420082,"eighty":-1.509183,"marketCap":175623557},{"date":"2022-07-08","current":-5.161369,"twenty":-7.620641,"median":-3.420082,"eighty":-1.509183,"marketCap":212116764},{"date":"2022-07-15","current":-4.939374,"twenty":-7.600302,"median":-3.420082,"eighty":-1.509183,"marketCap":202993462},{"date":"2022-07-22","current":-4.967124,"twenty":-7.582154,"median":-3.420082,"eighty":-1.509183,"marketCap":204133875},{"date":"2022-07-29","current":-4.495386,"twenty":-7.569092,"median":-3.420082,"eighty":-1.509183,"marketCap":184746859},{"date":"2022-08-05","current":-4.828377,"twenty":-7.552842,"median":-3.420082,"eighty":-1.509183,"marketCap":198431811},{"date":"2022-08-12","current":-4.959637,"twenty":-7.50861,"median":-3.420082,"eighty":-1.509183,"marketCap":195012917},{"date":"2022-08-19","current":-4.785614,"twenty":-7.441671,"median":-3.420082,"eighty":-1.509183,"marketCap":188170359},{"date":"2022-08-26","current":-4.147533,"twenty":-7.384548,"median":-3.420082,"eighty":-1.509183,"marketCap":163080978},{"date":"2022-09-02","current":-4.20554,"twenty":-7.353882,"median":-3.420082,"eighty":-1.509183,"marketCap":165361830},{"date":"2022-09-09","current":-4.292551,"twenty":-7.292493,"median":-3.420082,"eighty":-1.509183,"marketCap":168783110},{"date":"2022-09-16","current":-4.350559,"twenty":-7.23411,"median":-3.420082,"eighty":-1.509183,"marketCap":171063963},{"date":"2022-09-23","current":-4.118529,"twenty":-7.185667,"median":-3.420082,"eighty":-1.509183,"marketCap":161940551},{"date":"2022-09-30","current":-4.495577,"twenty":-7.131131,"median":-3.420082,"eighty":-1.509183,"marketCap":176766095},{"date":"2022-10-07","current":-3.799488,"twenty":-6.953497,"median":-3.420082,"eighty":-1.509183,"marketCap":149395861},{"date":"2022-10-14","current":-3.538454,"twenty":-6.76637,"median":-3.420082,"eighty":-1.509183,"marketCap":139132023},{"date":"2022-10-21","current":-3.567458,"twenty":-6.674372,"median":-3.418257,"eighty":-1.509183,"marketCap":140272449},{"date":"2022-10-28","current":-3.596462,"twenty":-6.528013,"median":-3.409536,"eighty":-1.509183,"marketCap":141412876},{"date":"2022-11-04","current":-3.306424,"twenty":-6.435942,"median":-3.39357,"eighty":-1.509183,"marketCap":130008611},{"date":"2022-11-11","current":-3.407341,"twenty":-6.335605,"median":-3.393436,"eighty":-1.509183,"marketCap":133431481},{"date":"2022-11-18","current":-3.989793,"twenty":-6.251734,"median":-3.393436,"eighty":-1.509183,"marketCap":156240281},{"date":"2022-11-25","current":-4.193651,"twenty":-6.184618,"median":-3.393436,"eighty":-1.509183,"marketCap":164223361},{"date":"2022-12-02","current":-4.717857,"twenty":-6.013388,"median":-3.393436,"eighty":-1.509183,"marketCap":184751281},{"date":"2022-12-09","current":-4.601367,"twenty":-5.8031,"median":-3.393436,"eighty":-1.509183,"marketCap":180189521},{"date":"2022-12-16","current":-4.426631,"twenty":-5.727576,"median":-3.393436,"eighty":-1.509183,"marketCap":173346881},{"date":"2022-12-23","current":-4.368386,"twenty":-5.610336,"median":-3.393436,"eighty":-1.509183,"marketCap":171066001},{"date":"2022-12-30","current":-4.513999,"twenty":-5.561222,"median":-3.393436,"eighty":-1.509183,"marketCap":176768201},{"date":"2023-01-06","current":-5.067328,"twenty":-5.484318,"median":-3.393436,"eighty":-1.509183,"marketCap":198436561},{"date":"2023-01-13","current":-5.329431,"twenty":-5.418781,"median":-3.393436,"eighty":-1.509183,"marketCap":208700521},{"date":"2023-01-20","current":-6.086618,"twenty":-5.418781,"median":-3.393436,"eighty":-1.509183,"marketCap":238351962},{"date":"2023-01-27","current":-8.008708,"twenty":-5.418781,"median":-3.393436,"eighty":-1.509183,"marketCap":313621002},{"date":"2023-02-03","current":-6.872928,"twenty":-5.418781,"median":-3.393436,"eighty":-1.509183,"marketCap":269143842},{"date":"2023-02-10","current":-7.105908,"twenty":-5.418781,"median":-3.393436,"eighty":-1.509183,"marketCap":278267362},{"date":"2023-02-17","current":-8.008708,"twenty":-5.418781,"median":-3.393436,"eighty":-1.509183,"marketCap":313621002},{"date":"2023-02-24","current":-7.368011,"twenty":-5.418781,"median":-3.393436,"eighty":-1.509183,"marketCap":288531322},{"date":"2023-03-03","current":-6.90205,"twenty":-5.418781,"median":-3.393436,"eighty":-1.509183,"marketCap":270284282},{"date":"2023-03-10","current":-6.144863,"twenty":-5.418781,"median":-3.393436,"eighty":-1.509183,"marketCap":240632842},{"date":"2023-03-17","current":-5.911883,"twenty":-5.418781,"median":-3.393436,"eighty":-1.509183,"marketCap":231509322},{"date":"2023-03-24","current":-5.824515,"twenty":-5.418781,"median":-3.393436,"eighty":-1.509183,"marketCap":228088002},{"date":"2023-03-31","current":-5.830308,"twenty":-5.430741,"median":-3.393436,"eighty":-1.510539,"marketCap":222426235},{"date":"2023-04-06","current":-5.052933,"twenty":-5.408841,"median":-3.393436,"eighty":-1.510539,"marketCap":192769403},{"date":"2023-04-14","current":-5.232327,"twenty":-5.29765,"median":-3.393436,"eighty":-1.509183,"marketCap":199613288},{"date":"2023-04-21","current":-5.501418,"twenty":-5.289761,"median":-3.393436,"eighty":-1.509183,"marketCap":209879114},{"date":"2023-04-28","current":-5.561216,"twenty":-5.289761,"median":-3.393436,"eighty":-1.509183,"marketCap":212160408},{"date":"2023-05-05","current":-5.680813,"twenty":-5.289761,"median":-3.393436,"eighty":-1.509183,"marketCap":216722998},{"date":"2023-05-12","current":-5.800409,"twenty":-5.289761,"median":-3.393436,"eighty":-1.509183,"marketCap":221285587},{"date":"2023-05-19","current":-7.226612,"twenty":-5.289761,"median":-3.393436,"eighty":-1.509183,"marketCap":292005724},{"date":"2023-05-26","current":-7.283156,"twenty":-5.344179,"median":-3.393436,"eighty":-1.509183,"marketCap":294290486},{"date":"2023-06-02","current":-8.271181,"twenty":-5.344179,"median":-3.393436,"eighty":-1.509183,"marketCap":334213614},{"date":"2023-06-09","current":-8.32764,"twenty":-5.344179,"median":-3.393436,"eighty":-1.509183,"marketCap":336494936},{"date":"2023-06-16","current":-8.976913,"twenty":-5.344179,"median":-3.393436,"eighty":-1.509183,"marketCap":362730134},{"date":"2023-06-23","current":-8.242952,"twenty":-5.335182,"median":-3.393436,"eighty":-1.507826,"marketCap":333072953},{"date":"2023-06-30","current":-7.621907,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":307978416},{"date":"2023-07-07","current":-8.497015,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":343338900},{"date":"2023-07-14","current":-9.132174,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":369003768},{"date":"2023-07-21","current":-11.632389,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":470029958},{"date":"2023-07-28","current":-10.963861,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":443016742},{"date":"2023-08-04","current":-11.933227,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":482185905},{"date":"2023-08-11","current":-12.1601,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":519066013},{"date":"2023-08-18","current":-10.893423,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":464996637},{"date":"2023-08-25","current":-11.590095,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":494734794},{"date":"2023-09-01","current":-11.463427,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":489327856},{"date":"2023-09-08","current":-12.033432,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":513659075},{"date":"2023-09-15","current":-11.653429,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":497438262},{"date":"2023-09-22","current":-12.1601,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":519066013},{"date":"2023-09-29","current":-11.970098,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":510955606},{"date":"2023-10-06","current":-11.938431,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":509603872},{"date":"2023-10-13","current":-10.355085,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":442017152},{"date":"2023-10-20","current":-10.101749,"twenty":-5.324018,"median":-3.393436,"eighty":-1.50647,"marketCap":431203276},{"date":"2023-10-27","current":-11.115091,"twenty":-5.29189,"median":-3.381076,"eighty":-1.505113,"marketCap":474458777},{"date":"2023-11-03","current":-11.400093,"twenty":-5.29189,"median":-3.381076,"eighty":-1.505113,"marketCap":486624387},{"date":"2023-11-10","current":-9.426398,"twenty":-5.29189,"median":-3.381076,"eighty":-1.505113,"marketCap":460941433},{"date":"2023-11-17","current":-9.977799,"twenty":-5.29189,"median":-3.381076,"eighty":-1.505113,"marketCap":487904391},{"date":"2023-11-24","current":-10.517513,"twenty":-5.313191,"median":-3.381076,"eighty":-1.505113,"marketCap":514295891},{"date":"2023-12-01","current":-10.655902,"twenty":-5.338428,"median":-3.381076,"eighty":-1.505113,"marketCap":521062942},{"date":"2023-12-08","current":-11.126422,"twenty":-5.415071,"median":-3.393436,"eighty":-1.505113,"marketCap":544070916},{"date":"2023-12-15","current":-12.316562,"twenty":-5.475519,"median":-3.393436,"eighty":-1.505113,"marketCap":602267556},{"date":"2023-12-22","current":-12.980826,"twenty":-5.561216,"median":-3.393436,"eighty":-1.505113,"marketCap":634749402},{"date":"2023-12-29","current":-13.340635,"twenty":-5.590213,"median":-3.381076,"eighty":-1.505113,"marketCap":652343735},{"date":"2024-01-05","current":-12.039785,"twenty":-5.620881,"median":-3.368717,"eighty":-1.505113,"marketCap":588733454},{"date":"2024-01-12","current":-11.596942,"twenty":-5.710712,"median":-3.368717,"eighty":-1.505113,"marketCap":567078890},{"date":"2024-01-19","current":-11.818364,"twenty":-5.829149,"median":-3.367888,"eighty":-1.505113,"marketCap":577906172},{"date":"2024-01-26","current":-13.783478,"twenty":-5.911883,"median":-3.368717,"eighty":-1.505113,"marketCap":673998299},{"date":"2024-02-02","current":-14.0049,"twenty":-6.006255,"median":-3.368717,"eighty":-1.505113,"marketCap":684825581},{"date":"2024-02-09","current":-13.202247,"twenty":-6.098621,"median":-3.368717,"eighty":-1.505113,"marketCap":645576684},{"date":"2024-02-16","current":-13.755801,"twenty":-6.227598,"median":-3.368717,"eighty":-1.505113,"marketCap":672644889},{"date":"2024-02-23","current":-13.589734,"twenty":-6.366195,"median":-3.368717,"eighty":-1.505113,"marketCap":664524427},{"date":"2024-03-01","current":-13.977222,"twenty":-6.479218,"median":-3.381076,"eighty":-1.505113,"marketCap":683472171},{"date":"2024-03-08","current":-13.831517,"twenty":-6.90205,"median":-3.381076,"eighty":-1.505113,"marketCap":756556324},{"date":"2024-03-15","current":-11.769541,"twenty":-7.041838,"median":-3.381076,"eighty":-1.505113,"marketCap":643770337},{"date":"2024-03-22","current":-12.350441,"twenty":-7.184539,"median":-3.381076,"eighty":-1.505113,"marketCap":675544409},{"date":"2024-03-28","current":-12.249415,"twenty":-7.248225,"median":-3.381076,"eighty":-1.505113,"marketCap":670018483},{"date":"2024-04-05","current":-11.643258,"twenty":-7.32724,"median":-3.368717,"eighty":-1.505113,"marketCap":636862930},{"date":"2024-04-12","current":-13.486984,"twenty":-7.368011,"median":-3.368717,"eighty":-1.505113,"marketCap":737711072},{"date":"2024-04-19","current":-12.100371,"twenty":-7.497698,"median":-3.368717,"eighty":-1.505113,"marketCap":661866110},{"date":"2024-04-26","current":-11.241472,"twenty":-7.68836,"median":-3.381076,"eighty":-1.505113,"marketCap":614886052},{"date":"2024-05-03","current":-11.822492,"twenty":-7.80485,"median":-3.381076,"eighty":-1.505113,"marketCap":646666679},{"date":"2024-05-10","current":-10.864479,"twenty":-8.073576,"median":-3.381076,"eighty":-1.505113,"marketCap":700617677},{"date":"2024-05-17","current":-10.114466,"twenty":-8.073576,"median":-3.381076,"eighty":-1.505113,"marketCap":652251565},{"date":"2024-05-24","current":-8.935874,"twenty":-8.073576,"median":-3.381076,"eighty":-1.505113,"marketCap":576247675},{"date":"2024-05-31","current":-8.8073,"twenty":-8.073576,"median":-3.381076,"eighty":-1.505113,"marketCap":567956342},{"date":"2024-06-07","current":-8.614439,"twenty":-8.073576,"median":-3.381076,"eighty":-1.505113,"marketCap":555519341},{"date":"2024-06-14","current":-8.700155,"twenty":-8.073576,"median":-3.393436,"eighty":-1.505113,"marketCap":561046897},{"date":"2024-06-21","current":-7.971571,"twenty":-8.211511,"median":-3.393487,"eighty":-1.505113,"marketCap":514062674},{"date":"2024-06-28","current":-8.164431,"twenty":-8.254244,"median":-3.407341,"eighty":-1.505113,"marketCap":526499674},{"date":"2024-07-05","current":-11.041081,"twenty":-8.350223,"median":-3.420082,"eighty":-1.505113,"marketCap":712006195},{"date":"2024-07-12","current":-12.928009,"twenty":-8.542182,"median":-3.422439,"eighty":-1.505113,"marketCap":833688547},{"date":"2024-07-15","current":-12.469027,"twenty":-8.611735,"median":-3.435172,"eighty":-1.505113,"marketCap":804090137},{"date":"2024-08-02","current":-11.576561,"twenty":-8.657297,"median":-3.483445,"eighty":-1.495778,"marketCap":746537673},{"date":"2024-08-09","current":-10.327108,"twenty":-8.743013,"median":-3.517337,"eighty":-1.495778,"marketCap":665964224},{"date":"2024-08-16","current":-9.860251,"twenty":-8.835767,"median":-3.540281,"eighty":-1.495778,"marketCap":742348719},{"date":"2024-08-23","current":-9.64162,"twenty":-8.935874,"median":-3.567458,"eighty":-1.495778,"marketCap":725888659},{"date":"2024-08-30","current":-9.226222,"twenty":-8.976913,"median":-3.594054,"eighty":-1.495778,"marketCap":694614544},{"date":"2024-09-06","current":-9.92584,"twenty":-9.085876,"median":-3.621282,"eighty":-1.495778,"marketCap":747286737},{"date":"2024-09-13","current":-9.269948,"twenty":-9.204358,"median":-3.662907,"eighty":-1.495778,"marketCap":697906556},{"date":"2024-09-20","current":-10.144471,"twenty":-9.278737,"median":-3.69958,"eighty":-1.495778,"marketCap":763746797},{"date":"2024-09-27","current":-9.269948,"twenty":-9.335537,"median":-3.746155,"eighty":-1.495778,"marketCap":697906556},{"date":"2024-10-04","current":-8.329835,"twenty":-9.335537,"median":-3.778343,"eighty":-1.505113,"marketCap":627128297},{"date":"2024-10-11","current":-7.87071,"twenty":-9.335537,"median":-3.801653,"eighty":-1.528294,"marketCap":592562170},{"date":"2024-10-18","current":-7.980026,"twenty":-9.335537,"median":-3.834375,"eighty":-1.549946,"marketCap":600792200},{"date":"2024-10-25","current":-7.30227,"twenty":-9.335537,"median":-3.860545,"eighty":-1.556351,"marketCap":549766014},{"date":"2024-10-31","current":-7.958163,"twenty":-9.335537,"median":-3.893503,"eighty":-1.562755,"marketCap":599146194},{"date":"2024-11-08","current":-8.78896,"twenty":-9.353709,"median":-3.91265,"eighty":-1.576715,"marketCap":661694424},{"date":"2024-11-15","current":-6.601047,"twenty":-9.353709,"median":-3.968149,"eighty":-1.588088,"marketCap":547464431},{"date":"2024-11-22","current":-6.704512,"twenty":-9.353709,"median":-4.002514,"eighty":-1.599903,"marketCap":556045378},{"date":"2024-11-29","current":-6.952827,"twenty":-9.353709,"median":-4.031518,"eighty":-1.612485,"marketCap":576639651},{"date":"2024-12-06","current":-7.449457,"twenty":-9.353709,"median":-4.06865,"eighty":-1.643185,"marketCap":617828198},{"date":"2024-12-13","current":-6.932134,"twenty":-9.353709,"median":-4.119828,"eighty":-1.655744,"marketCap":574923462},{"date":"2024-12-20","current":-8.157595,"twenty":-9.353709,"median":-4.147533,"eighty":-1.664831,"marketCap":676558329},{"date":"2024-12-27","current":-8.283874,"twenty":-9.353709,"median":-4.176536,"eighty":-1.687705,"marketCap":687031368},{"date":"2025-01-03","current":-7.753504,"twenty":-9.353709,"median":-4.193651,"eighty":-1.695455,"marketCap":643044603},{"date":"2025-01-10","current":-7.677737,"twenty":-9.371881,"median":-4.217893,"eighty":-1.693654,"marketCap":636760780},{"date":"2025-01-17","current":-7.349413,"twenty":-9.371881,"median":-4.24322,"eighty":-1.693654,"marketCap":609530878},{"date":"2025-01-24","current":-7.273645,"twenty":-9.371881,"median":-4.263547,"eighty":-1.693654,"marketCap":603247055},{"date":"2025-01-31","current":-7.0716,"twenty":-9.371881,"median":-4.295751,"eighty":-1.693654,"marketCap":586490192},{"date":"2025-02-07","current":-7.172623,"twenty":-9.371881,"median":-4.324072,"eighty":-1.708924,"marketCap":594868623},{"date":"2025-02-14","current":-7.147367,"twenty":-9.371881,"median":-4.350344,"eighty":-1.740807,"marketCap":592774015},{"date":"2025-02-21","current":-6.793787,"twenty":-9.371881,"median":-4.368299,"eighty":-1.740807,"marketCap":563449506},{"date":"2025-02-28","current":-6.212905,"twenty":-9.371881,"median":-4.377594,"eighty":-1.761302,"marketCap":515273526},{"date":"2025-03-07","current":-6.566485,"twenty":-9.390054,"median":-4.397509,"eighty":-1.766426,"marketCap":544598035},{"date":"2025-03-14","current":-6.970577,"twenty":-9.390054,"median":-4.426631,"eighty":-1.849687,"marketCap":578111761},{"date":"2025-03-21","current":-7.223134,"twenty":-9.390054,"median":-4.455754,"eighty":-2.630922,"marketCap":599057839},{"date":"2025-03-28","current":-6.073163,"twenty":-9.390054,"median":-4.529252,"eighty":-2.706091,"marketCap":582300976},{"date":"2025-04-04","current":-6.365989,"twenty":-9.390054,"median":-4.555508,"eighty":-2.731148,"marketCap":610377439},{"date":"2025-04-11","current":-5.795246,"twenty":-9.371881,"median":-4.597373,"eighty":-2.756204,"marketCap":555653944},{"date":"2025-04-17","current":-6.431845,"twenty":-9.371881,"median":-4.606018,"eighty":-2.78126,"marketCap":616691688},{"date":"2025-04-25","current":-7.178202,"twenty":-9.390054,"median":-4.631607,"eighty":-2.806317,"marketCap":688253181},{"date":"2025-05-02","current":-7.15625,"twenty":-9.390054,"median":-4.638411,"eighty":-2.831373,"marketCap":686148431},{"date":"2025-05-09","current":-7.072289,"twenty":-9.390054,"median":-4.657196,"eighty":-2.85643,"marketCap":678098122},{"date":"2025-05-16","current":-6.413042,"twenty":-9.390054,"median":-4.661881,"eighty":-2.873318,"marketCap":655246189},{"date":"2025-05-23","current":-6.041869,"twenty":-9.390054,"median":-4.688734,"eighty":-2.888127,"marketCap":617321972},{"date":"2025-05-30","current":-4.61904,"twenty":-9.390054,"median":-4.689631,"eighty":-2.910465,"marketCap":471945808},{"date":"2025-06-06","current":-4.90773,"twenty":-9.390054,"median":-4.717857,"eighty":-2.931599,"marketCap":501442421},{"date":"2025-06-13","current":-4.660282,"twenty":-9.390054,"median":-4.745129,"eighty":-2.956655,"marketCap":476159610},{"date":"2025-06-20","current":-4.268488,"twenty":-9.408226,"median":-4.745129,"eighty":-2.972398,"marketCap":436128492},{"date":"2025-06-27","current":-4.557178,"twenty":-9.408226,"median":-4.745129,"eighty":-2.997168,"marketCap":465625105},{"date":"2025-07-03","current":-4.515937,"twenty":-9.408226,"median":-4.745129,"eighty":-3.006768,"marketCap":461411303},{"date":"2025-07-11","current":-4.742764,"twenty":-9.408226,"median":-4.751796,"eighty":-3.031824,"marketCap":484587213},{"date":"2025-07-18","current":-4.825247,"twenty":-9.408226,"median":-4.769744,"eighty":-3.056881,"marketCap":493014817},{"date":"2025-07-25","current":-5.258282,"twenty":-9.408226,"median":-4.785378,"eighty":-3.076726,"marketCap":537259737},{"date":"2025-08-01","current":-5.340765,"twenty":-9.408226,"median":-4.825247,"eighty":-3.084799,"marketCap":545687340},{"date":"2025-08-08","current":-5.423248,"twenty":-9.408226,"median":-4.864376,"eighty":-3.106994,"marketCap":554114944},{"date":"2025-08-15","current":-5.747899,"twenty":-9.408226,"median":-4.911625,"eighty":-3.127725,"marketCap":634177179},{"date":"2025-08-22","current":-5.824283,"twenty":-9.408226,"median":-4.939374,"eighty":-3.147266,"marketCap":642604783},{"date":"2025-08-29","current":-6.244395,"twenty":-9.408226,"median":-4.968358,"eighty":-3.163746,"marketCap":688956604},{"date":"2025-09-05","current":-6.836371,"twenty":-9.426398,"median":-5.052933,"eighty":-3.178816,"marketCap":754270532},{"date":"2025-09-12","current":-6.855467,"twenty":-9.408226,"median":-5.072724,"eighty":-3.195327,"marketCap":756377433},{"date":"2025-09-19","current":-6.874563,"twenty":-9.408226,"median":-5.134558,"eighty":-3.195327,"marketCap":758484334},{"date":"2025-09-26","current":-6.626315,"twenty":-9.408226,"median":-5.15883,"eighty":-3.205742,"marketCap":731094622},{"date":"2025-10-03","current":-6.664507,"twenty":-9.408226,"median":-5.198379,"eighty":-3.220097,"marketCap":735308424},{"date":"2025-10-10","current":-6.530835,"twenty":-9.408226,"median":-5.24421,"eighty":-3.232276,"marketCap":720560118},{"date":"2025-10-17","current":-6.836371,"twenty":-9.408226,"median":-5.289213,"eighty":-3.245577,"marketCap":754270532},{"date":"2025-10-24","current":-7.867556,"twenty":-9.408226,"median":-5.346344,"eighty":-3.257332,"marketCap":868043183},{"date":"2025-10-31","current":-8.211284,"twenty":-9.408226,"median":-5.417485,"eighty":-3.269637,"marketCap":905967399},{"date":"2025-11-07","current":-8.627061,"twenty":-9.408226,"median":-5.493264,"eighty":-3.282388,"marketCap":951840860},{"date":"2025-11-14","current":-9.317583,"twenty":-9.418263,"median":-5.561814,"eighty":-3.307084,"marketCap":1028027528},{"date":"2025-11-21","current":-9.745075,"twenty":-9.444852,"median":-5.606096,"eighty":-3.315062,"marketCap":1126969144},{"date":"2025-11-28","current":-13.125593,"twenty":-9.545423,"median":-5.665864,"eighty":-3.336451,"marketCap":1517909190},{"date":"2025-12-05","current":-13.292532,"twenty":-9.616636,"median":-5.72393,"eighty":-3.357699,"marketCap":1537214871},{"date":"2025-12-12","current":-14.481974,"twenty":-9.680973,"median":-5.814735,"eighty":-3.36739,"marketCap":1674767851},{"date":"2025-12-19","current":-12.645643,"twenty":-9.812152,"median":-5.830308,"eighty":-3.393446,"marketCap":1462405356},{"date":"2025-12-26","current":-13.355134,"twenty":-9.912722,"median":-5.859766,"eighty":-3.396324,"marketCap":1544454502},{"date":"2026-01-02","current":-12.583041,"twenty":-10.058665,"median":-5.911883,"eighty":-3.418622,"marketCap":1455165726},{"date":"2026-01-09","current":-12.019621,"twenty":-10.141582,"median":-5.999939,"eighty":-3.422439,"marketCap":1390009052},{"date":"2026-01-16","current":-12.27003,"twenty":-10.265424,"median":-6.039292,"eighty":-3.450393,"marketCap":1418967574},{"date":"2026-01-23","current":-13.480339,"twenty":-10.320481,"median":-6.082171,"eighty":-3.481646,"marketCap":1558933763},{"date":"2026-01-30","current":-11.644008,"twenty":-10.355085,"median":-6.120046,"eighty":-3.517337,"marketCap":1346571269},{"date":"2026-02-06","current":-11.024995,"twenty":-10.513189,"median":-6.1897,"eighty":-3.539185,"marketCap":1274985540},{"date":"2026-02-13","current":-12.456535,"twenty":-10.658057,"median":-6.270837,"eighty":-3.567458,"marketCap":1440535988},{"date":"2026-02-20","current":-12.221506,"twenty":-10.788754,"median":-6.304726,"eighty":-3.59261,"marketCap":1413356064},{"date":"2026-02-27","current":-12.755663,"twenty":-10.863582,"median":-6.365989,"eighty":-3.635157,"marketCap":1475128619},{"date":"2026-03-06","current":-11.730082,"twenty":-10.950423,"median":-6.398917,"eighty":-3.662907,"marketCap":1356525313},{"date":"2026-03-13","current":-11.366855,"twenty":-11.041081,"median":-6.437781,"eighty":-3.70985,"marketCap":1314519975},{"date":"2026-03-20","current":-10.996658,"twenty":-11.102424,"median":-6.471176,"eighty":-3.70985,"marketCap":1306809788},{"date":"2026-03-27","current":-11.18846,"twenty":-11.124156,"median":-6.558208,"eighty":-3.713082,"marketCap":1329602982},{"date":"2026-04-02","current":-11.891734,"twenty":-11.144755,"median":-6.577787,"eighty":-3.731396,"marketCap":1413178027},{"date":"2026-04-10","current":-12.509763,"twenty":-11.235196,"median":-6.607458,"eighty":-3.731396,"marketCap":1486622763},{"date":"2026-04-17","current":-12.032162,"twenty":-11.266721,"median":-6.643922,"eighty":-3.731396,"marketCap":1429866065},{"date":"2026-04-24","current":-10.538809,"twenty":-11.291542,"median":-6.694014,"eighty":-3.731396,"marketCap":1252400418},{"date":"2026-05-01","current":-11.178817,"twenty":-11.291542,"median":-6.721333,"eighty":-3.731396,"marketCap":1328457124},{"date":"2026-05-08","current":-11.011526,"twenty":-11.307445,"median":-6.744587,"eighty":-3.746155,"marketCap":1308576748},{"date":"2026-05-15","current":-10.321688,"twenty":-11.307445,"median":-6.795983,"eighty":-3.771168,"marketCap":1336472764},{"date":"2026-05-22","current":-9.910387,"twenty":-11.307445,"median":-6.836371,"eighty":-3.771168,"marketCap":1283216733},{"date":"2026-05-29","current":-9.969144,"twenty":-11.310289,"median":-6.869554,"eighty":-3.770484,"marketCap":1290824738},{"date":"2026-06-05","current":-10.380445,"twenty":-11.307445,"median":-6.884111,"eighty":-3.771168,"marketCap":1344080768},{"date":"2026-06-12","current":-10.321688,"twenty":-11.307445,"median":-6.916951,"eighty":-3.771168,"marketCap":1336472764},{"date":"2026-06-18","current":-10.537131,"twenty":-11.307445,"median":-6.945321,"eighty":-3.771168,"marketCap":1364368780},{"date":"2026-06-26","current":-11.810204,"twenty":-11.366855,"median":-6.960295,"eighty":-3.770484,"marketCap":1529208874},{"date":"2026-07-02","current":-11.868962,"twenty":-11.430954,"median":-6.995833,"eighty":-3.770484,"marketCap":1536816878},{"date":"2026-07-10","current":-12.319434,"twenty":-11.465257,"median":-7.021088,"eighty":-3.770484,"marketCap":1595144912},{"date":"2026-07-17","current":-10.811331,"twenty":-11.465257,"median":-7.068444,"eighty":-3.801653,"marketCap":1399872800},{"date":"2026-07-24","current":-11.261803,"twenty":-11.465257,"median":-7.0716,"eighty":-3.829402,"marketCap":1458200833},{"date":"2026-07-31","current":-10.850503,"twenty":-11.474987,"median":-7.100696,"eighty":-3.857152,"marketCap":1404944803},{"date":"2026-08-07","current":-11.340146,"twenty":-11.474987,"median":-7.128205,"eighty":-3.94329,"marketCap":1468344839},{"date":"2026-08-14","current":-9.613933,"twenty":-11.474987,"median":-7.15625,"eighty":-4.025717,"marketCap":1339307365},{"date":"2026-08-21","current":-10.015273,"twenty":-11.474987,"median":-7.185996,"eighty":-4.075421,"marketCap":1395217729},{"date":"2026-08-28","current":-10.015273,"twenty":-11.474987,"median":-7.210994,"eighty":-4.145108,"marketCap":1395217729},{"date":"2026-08-31","current":-9.59569,"twenty":-11.474987,"median":-7.222117,"eighty":-4.147533,"marketCap":1336765985}],"updateTime":1788261458158},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SVRA\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2627266568","title":"A Look At Savara (SVRA) Valuation After Strong 1 Year Shareholder Return","url":"https://stock-news.laohu8.com/highlight/detail?id=2627266568","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627266568?lang=en_us&edition=fundamental","pubTime":"2026-04-16 13:09","pubTimestamp":1776316161,"startTime":"0","endTime":"0","summary":"Recent share performance and business profile\nSavara (SVRA) has drawn attention after a month return of about 12%, following a relatively flat past 3 months. The move comes as investors reassess this US$1.5b clinical stage rare disease developer.\nSee our latest analysis for Savara.\nDespite a softer 1-day share price return of 3.29% and a 7-day share price return of 1.18%, Savara’s 12.24% 30-day share price return sits alongside a very large 1-year total shareholder return of around 100%,...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-svra/savara/news/a-look-at-savara-svra-valuation-after-strong-1-year-sharehol","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-svra/savara/news/a-look-at-savara-svra-valuation-after-strong-1-year-sharehol","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627223772","title":"Savara publishes corporate presentation highlighting MOLBREEVI program in autoimmune PAP","url":"https://stock-news.laohu8.com/highlight/detail?id=2627223772","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627223772?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:14","pubTimestamp":1776284080,"startTime":"0","endTime":"0","summary":"Savara highlighted Phase 3 IMPALA-2 data for MOLBREEVI, an inhaled molgramostim program for autoimmune pulmonary alveolar proteinosis.Trial met primary endpoint, with Week 24 DLCO least-squares mean change 9.8 for MOLBREEVI vs 3.8 for placebo; between-group difference 6 .Week 48 DLCO least-squares mean change was 11.6 vs 4.7; between-group difference 6.9 .Quality-of-life endpoint favored MOLBREEVI at Week 24, with SGRQ total score change -11.5 vs -4.9; between-group difference -6.59 .Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief on April 15, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL3d5MkR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627237416","title":"FDA extends Savara molgramostim BLA review, pushing PDUFA date to Nov. 22, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2627237416","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627237416?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:06","pubTimestamp":1776283577,"startTime":"0","endTime":"0","summary":"FDA extended review period for molgramostim inhalation solution BLA in autoimmune pulmonary alveolar proteinosis by three months.PDUFA target action date moved to Nov. 22, 2026.Extension followed FDA determination that Savara responses to information requests constituted a major amendment to the BLA.FDA correspondence did not cite safety, efficacy, or manufacturing concerns.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL9RDDDV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627237153","title":"Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (Bla) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune Pap)","url":"https://stock-news.laohu8.com/highlight/detail?id=2627237153","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627237153?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:05","pubTimestamp":1776283501,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nTUA56TY7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627237121","title":"Savara Inc: Prescription Drug User Fee Act (Pdufa) Target Action Date Extended by Three Months to November 22, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2627237121","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627237121?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:05","pubTimestamp":1776283501,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nTUA56TY7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627445415","title":"Savara presents new Phase 3 IMPALA-2 molgramostim data at ATS 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2627445415","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627445415?lang=en_us&edition=fundamental","pubTime":"2026-04-14 20:09","pubTimestamp":1776168598,"startTime":"0","endTime":"0","summary":"Savara set three presentations for ATS 2026 in Orlando, featuring new Phase 3 IMPALA-2 data on inhaled molgramostim for autoimmune pulmonary alveolar proteinosis.Results will be presented in the future, with one oral session on May 18, 2026, focused on improved patient exercise performance.Two poster sessions on May 19-20, 2026, will highlight longer-term efficacy and safety from ongoing open-label treatment, alongside data linking lung function with biomarker levels.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL3dbmQd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626514882","title":"Savara announces annual shareholder meeting via webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2626514882","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626514882?lang=en_us&edition=fundamental","pubTime":"2026-04-11 04:19","pubTimestamp":1775852399,"startTime":"0","endTime":"0","summary":"Savara scheduled 2026 annual stockholders meeting for June 4, 2026, via virtual webcast.Shareholders will vote to elect six directors for one-year terms.Ballot includes proposal to increase authorized common shares to 600,000,000 from 300,000,000.Company also seeks approval to expand 2024 Omnibus Incentive Plan share pool by 18,900,000 shares.Additional items include ratification of RSM as independent auditor for fiscal 2026, advisory vote on executive pay.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 10, 2026, and is sol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL3bYnGx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625995335","title":"BUZZ-Savara rises as UK accepts application for rare lung disease drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2625995335","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625995335?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:46","pubTimestamp":1775565962,"startTime":"0","endTime":"0","summary":"BUZZ-Savara rises as UK accepts application for rare lung disease drug** Shares of biotech firm Savara SVRA.O rise 2% to $5.70 premarket ** Co says UK drug regulator has accepted application for Molbreevi to treat autoimmune pulmonary alveolar proteinosis** The rare lung disease causes a build-up of material in the air sacs, making it hard for patients to breathe** UK regulator will review the drug under an accelerated process, with a decision expected in Q4 2026, co says** Says Molbreevi is an inhaled drug designed to help the lungs clear the build-up** Reviews of the drug are also underway in the U.S. and Europe, with FDA action due in August 2026 and EU decision expected in Q1 2027, co says** As of last close, stock down ~7% YTD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nL4N40Q0VQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625958830","title":"Savara Announces The U.K. Medicines And Healthcare Products Regulatory Agency (Mhra) Has Accepted The Molbreevi* Marketing Authorisation Application (Maa) For Autoimmune Pulmonary Alveolar Prote","url":"https://stock-news.laohu8.com/highlight/detail?id=2625958830","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625958830?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:20","pubTimestamp":1775564443,"startTime":"0","endTime":"0","summary":"April 7 (Reuters) - Savara Inc ::*SAVARA ANNOUNCES THE U.K. MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY (MHRA) HAS ACCEPTED THE MOLBREEVI* MARKETING AUTHORISATION APPLICATION (MAA) FOR AUTOIMM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nRSD6l85Vt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625930083","title":"Savara publishes corporate presentation highlighting MOLBREEVI autoimmune PAP Phase 3 data","url":"https://stock-news.laohu8.com/highlight/detail?id=2625930083","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625930083?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:19","pubTimestamp":1775564398,"startTime":"0","endTime":"0","summary":"Savara highlighted Phase 3 IMPALA-2 data for MOLBREEVI  in autoimmune pulmonary alveolar proteinosis, with primary endpoint met on change in DLCO% at Week 24 .Least-squares mean DLCO% change from baseline was 9.8 for MOLBREEVI vs 3.8 for placebo at Week 24, a 6-point between-group difference.Week 48 DLCO% results also favored MOLBREEVI, with least-squares mean change 11.6 vs 4.7 for placebo, a 6.9-point between-group difference .Health-status measures improved, with SGRQ total score change -11.5 for MOLBREEVI vs -4.9 for placebo at Week 24 .Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief on April 07, 2026, and is solely responsible for the information contained","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDLcgq2nm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625958853","title":"Savara announces MHRA accepted submission of Molbreevi MAA","url":"https://stock-news.laohu8.com/highlight/detail?id=2625958853","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625958853?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:11","pubTimestamp":1775563903,"startTime":"0","endTime":"0","summary":"Savara (SVRA) announced that the MHRA has accepted the submission of the Molbreevi MAA for the treatment of autoimmune PAP in the U.K. The MAA was ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/savara-announces-mhra-accepted-submission-of-molbreevi-maa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/savara-announces-mhra-accepted-submission-of-molbreevi-maa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4585","SVRA","BK4215","MAA","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625924930","title":"Savara says UK MHRA accepts Molbreevi filing for autoimmune PAP under accelerated review","url":"https://stock-news.laohu8.com/highlight/detail?id=2625924930","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625924930?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:05","pubTimestamp":1775563533,"startTime":"0","endTime":"0","summary":"Savara said U.K. MHRA accepted marketing authorization application for Molbreevi to treat autoimmune pulmonary alveolar proteinosis.MHRA granted accelerated review with 150-day assessment; decision expected in Q4 2026.FDA review of Molbreevi biologics license application runs under priority review with Aug. 22, 2026 PDUFA date.EU application is under CHMP review with decision expected in Q1 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief via Business Wire  on April 07, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDLbvSsZG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625930968","title":"Savara Inc - Mhra Decision on Molbreevi Maa Expected in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2625930968","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625930968?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:05","pubTimestamp":1775563500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nTUA8Z88VG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625930966","title":"Savara Announces the U.k. Medicines and Healthcare Products Regulatory Agency (Mhra) Has Accepted the Molbreevi* Marketing Authorisation Application (Maa) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune Pap)","url":"https://stock-news.laohu8.com/highlight/detail?id=2625930966","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625930966?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:05","pubTimestamp":1775563500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nTUA8Z88VG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625930962","title":"Savara Inc - FDA Pdufa Date for Molbreevi Bla Set for August 22, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2625930962","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625930962?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:05","pubTimestamp":1775563500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nTUA8Z88VG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624554320","title":"A Look At Savara (SVRA) Valuation As MOLBREEVI Nears Key Regulatory Decisions In Rare Lung Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2624554320","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624554320?lang=en_us&edition=fundamental","pubTime":"2026-04-01 07:17","pubTimestamp":1774999028,"startTime":"0","endTime":"0","summary":"Savara (SVRA) is back in focus after regulators in Europe, the U.S. and the U.K. advanced reviews of its lead drug candidate MOLBREEVI for autoimmune pulmonary alveolar proteinosis, a rare chronic lung disease.\nSee our latest analysis for Savara.\nAt a share price of $5.46, Savara has seen an 8.12% 1 day share price return after the regulatory update, while its 1 year total shareholder return of 90.91% and 3 year total shareholder return of 219.30% signal strong longer term momentum despite...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-svra/savara/news/a-look-at-savara-svra-valuation-as-molbreevi-nears-key-regul","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-svra/savara/news/a-look-at-savara-svra-valuation-as-molbreevi-nears-key-regul","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623107213","title":"Savara publishes corporate presentation spotlighting MOLBREEVI Phase 3 progress in autoimmune PAP","url":"https://stock-news.laohu8.com/highlight/detail?id=2623107213","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623107213?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:45","pubTimestamp":1774874715,"startTime":"0","endTime":"0","summary":"Savara highlighted Phase 3 IMPALA-2 data for MOLBREEVI  in autoimmune pulmonary alveolar proteinosis, a rare lung disease with no approved drugs in US or Europe.Primary endpoint met at Week 24, with least-squares mean DLCO% change of 9.8 for MOLBREEVI versus 3.8 for placebo.Week 48 DLCO% also favored MOLBREEVI, with least-squares mean change of 11.6 versus 4.7 for placebo.Health status improved at Week 24, with SGRQ total score change of -11.5 for MOLBREEVI versus -4.9 for placebo.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief on March 30, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL6vsvcM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623177243","title":"Savara announces EMA validation of MAA for MOLBREEVI","url":"https://stock-news.laohu8.com/highlight/detail?id=2623177243","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623177243?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:19","pubTimestamp":1774873190,"startTime":"0","endTime":"0","summary":"Savara (SVRA) announced that the EMA has validated the submission of the MOLBREEVI MAA in autoimmune PAP; the submission will now be reviewed by th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/savara-announces-ema-validation-of-maa-for-molbreevi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/savara-announces-ema-validation-of-maa-for-molbreevi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA","SVRA","MAA","BK4081","BK4585","BK4139","BK4588","BK4215"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623731755","title":"Savara says EMA validates MOLBREEVI marketing application for autoimmune PAP","url":"https://stock-news.laohu8.com/highlight/detail?id=2623731755","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623731755?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:08","pubTimestamp":1774872494,"startTime":"0","endTime":"0","summary":"Savara said EMA validated marketing authorization application for Molbreevi in autoimmune pulmonary alveolar proteinosis, starting CHMP review.FDA is reviewing Molbreevi biologics license application under Priority Review with an Aug. 22, 2026 action date.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief via Business Wire  on March 30, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL4tTrCQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623394317","title":"Savara Inc - Molbreevi Bla Under FDA Priority Review With August 22, 2026 Action Date","url":"https://stock-news.laohu8.com/highlight/detail?id=2623394317","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623394317?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:05","pubTimestamp":1774872300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUAB86YWL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":108,"code":"91000000","status":"200"}]}}